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Abstract
Background:  Genomic instability has been reported at microsatellite tracts in few coding
sequences. We have shown that the Bloom syndrome BLM gene may be a target of
microsatelliteinstability (MSI) in a short poly-adenine repeat located in its coding region. To further
characterize the involvement of BLM in tumorigenesis, we have investigated mutations in nine genes
containing coding microsatellites in microsatellite mutator phenotype (MMP) positive and negative
gastric carcinomas (GCs).
Methods:  We analyzed 50 gastric carcinomas (GCs) for mutations in the BLM poly(A) tract aswell
as in the coding microsatellites of the TGFβ1-RII, IGFIIR, hMSH3, hMSH6, BAX, WRN, RECQL and CBL
genes.
Results:   BLM mutations were found in 27% of MMP+ GCs (4/15 cases) but not in any of the MMP
negative GCs (0/35 cases). The frequency of mutations in the other eight coding regions
microsatellite was the following: TGFβ1-RII (60 %), BAX (27%), hMSH6 (20%),hMSH3 (13%), CBL
(13%), IGFIIR (7%), RECQL (0%) and WRN (0%). Mutations in BLM appear to be more frequently
associated with frameshifts in BAX and in hMSH6and/or hMSH3. Tumors with BLM alterations
present a higher frequency of unstable mono- and trinucleotide repeats located in coding regions
as compared with mutator phenotype tumors without BLM frameshifts.
Conclusions:   BLM frameshifts are frequent alterations in GCs specifically associated with
MMP+tumors. We suggest that BLM loss of function by MSI may increase the genetic instability of
a pre-existent unstable genotype in gastric tumors.
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Cancer is a progressive genetic disease characterized by
progressive accumulation of mutations in both coding
and non-coding sequences [1]. Simple sequence repeats
or microsatellites are highly unstable in some human ne-
oplasms, identifying a class of tumors with the microsat-
ellite mutator phenotype (MMP+) (for review see [2]).
MMP+ve status is defined by instability in more than
30% of analised microsatellites, including at least one
mononucleotide (such as BAT26 or BAT25) [3]. Micros-
atellite instability (MSI) has been described as a frequent
genetic alteration in various human solid tumors includ-
ing sporadic and familial gastric carcinomas (GCs). In al-
most all patients with hereditary nonpolyposis colorectal
cancer (HNPCC), molecular studies have shown that
MSI is caused by germline mutations in genes encoding
proteins required for DNA mismatch repair (MMR) [4].
Genes such as hMSH2, hMLH1, PMS1, PMS2 and
hMSH6/GTBP[5–8], were defined as "caretakers" be-
cause, when disrupted, they favor the acquisition of mu-
tations at high frequency in several genes including
oncogenes and tumor suppressor genes [9]. However, in
a significant fraction of sporadic MMP+ tumors, muta-
tion analysis has not allowed the identification of the
genes responsible for MSI [2,10], suggesting that, in such
cases, MSI might be caused by epigenetic mechanisms.
In fact, gene silencing by promoter hypermethylation
was recently shown for the hMLH1 gene [11–13].
The significance of MSI in tumorigenesis has been sup-
ported by the demonstration that the genetic instability
characterizing MMP+ gastrointestinal cancers may tar-
get short repetitive tracts within the coding region of
genes important for cell survival and proliferation. Inser-
tion/deletion mutations were found in the genes for the
transforming growth factor-beta type II receptor
(TGFβ1-RII), the insulin-like growth factor type II recep-
tor (IGFIIR), the DNA mismatch-repair genes hMSH3
and hMSH6, the proapoptotic gene BAX and the tran-
scription factor E2F-4[14–18]. In all the cases, with the
exception of the E2F-4, the nucleotides insertion/dele-
tion resulted in frameshift mutations and protein trunca-
tion. Although the biological significance of these
alterations is not fully established, it was proposed that
the absence of TGFβ1-RII receptors from the surface of
gastrointestinal epithelial cells could eliminate the nega-
tive growth control of TGF-β, leading to uncontrolled cell
growth [19]. IGFIIR has a role in growth suppression by
binding and activating the TGFβ1 receptor complex and
by mediating internalization, with subsequent degrada-
tion, of the growth factor IGF-II [20,21]. BAX promotes
apoptosis and it was reported that BAX inactivation
leads to rapid tumor growth [22]. The human genes
hMSH3 and hMSH6 are homologous to the bacterial
MutS gene whose products bind DNA mismatches to in-
itiate strand-specific repair of DNA replication errors
[23]. Somatic and germline mutations in hMSH6 were
associated with sporadic MMP+ colorectal carcinomas
and HNPCC [6].
We have found previously that the BLM gene may also be
a target of MSI [24]. The frameshifts, found in a short
poly-adenine repeat, were predicted to generate a trun-
cated and non-functional BLM protein. Homozygous or
compound heterozygous mutations at the BLM gene
were shown to cause the Bloom syndrome (BS; OMIM
210900), a pre-malignant condition characterized by
chromosomal instability and increased mutational rate.
BS patients are predisposed to a wide variety of neo-
plams diagnosed at early age. Noteworthy, among 100
neoplasms recorded in the BS registry, 19 were gastroin-
testinal (esophagus, stomach and colon) and only two
were diagnosed after the age of 40 [25]. These data indi-
cate that mutations in the BLM gene can promote tumor-
igenesis.
To better define the role of BLM in gastrointestinal tum-
origenesis we screened a panel of MMP+ and MMP- gas-
tric carcinomas (GCs) for: a) frameshifts in the BLM
coding region microsatellite and b) for possible associa-
tions with other intragenic frameshifts.
Results
MSI status
For the present study, our panel of 50 GCs contains 15
MMP+ tumors with MSI at two or more loci (Table 2)
and 35 GCs MMP- with alteration at one microsatellite (4
tumors) or without MSI (31 tumors). All the MMP+ cases
were BAT 26 positive, and BAT 25 instability was found
in 13 out of 15 cases (except cases 67R and 27P). The clin-
ico-pathological features of MMP+ tumors are described
in Table 1. The MMP+ phenotype was closely associated
with a low pTNM stage and with a less prevalent nodal
metastases (p = 0.02 and p = 0.001 at Fisher exact test,
respectively, vs. MMP-tumors). Within the MMP+
group, an excess of tumors in early stages and without
lymph node metastasis was found (10/15 cases vs. 10/32
cases of MMP- cases, p = 0.02 and 11/15 cases vs. 7/32
cases of MMP- cases, p = 0.001, respectively), data that
support the proposed better prognostic of GCs MMP+
[33,34]. Of note, no excess of intestinal type among
MMP+ tumors was found (12/15 cases vs. 20/32 of
MMP- cases) (Table 1), data in accordance with recent
studies showing no significant difference in the frequen-
cy of MSI in intestinal-type and diffuse-type carcinomas
[26,35].
BLM frameshifts
PCR amplification of the BLM microsatellite revealed ab-
normal bands, absent in the normal matched DNAs, in 4
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Variable Number of patients P valueb
Total (%) MMP+ (%) MMP-(%)
Histotype
Intestinal 32(68.0) 12(37.5) 20(62.5)
Diffuse + Mixed 15(32.0) 3(20.0) 12(80.0) NSc
T (depth of wall infiltration)
T1 + T2 12(25.5) 6(50.0) 6(50.0)
T3 + T4 35(74.5) 9(25.7) 26(74.3) NS
N (lymph node status)
N0 18(38.3) 11(78.5) 7(21.5)
N+ 29(61.7) 4(12.1) 25(87.9) = 0.001
M (metastases)
M0 40(85.1) 14(35.0) 26(65.0)
M+ 7(14.9) 1(14.2) 6(85.8) NS
Staging
I + II 20(42.5) 10(58.8) 10(41.2)
III + IV 27(57.5) 5(16.6) 22(83.4) = 0.02
Totala 47 15 32
a – data were available for 47 out of 50 cases b – at Fisher exact test c – NS = not statistically significant
Table 2: Status of the coding microsatellites within BLM, WRN, RECQL, CBL, hMSH6, hMSH3,IGFIIR,TGF-βRII and BAX genes in the series 
of gastric carcinomas with microsatellite mutator phenotype.
Case Histotypea Stagingb BLM WRN REQL CBL hMSH6 hMSH3 IGFIIR TGF-βRII BAX
No. MSIc (A)9 (A)8 (A)9 (ATG)6 (C)8 (A)8 (G)8 (A)10 (G)8
31R I I(T2N0M0) 2/5 - - - - - - - - -
57R I IV(T3N1M1
)
5/5 - - - - - - - + -
63R I I(T2N0M0) 5/5 - - - - + - - + +
67R I I(T2N0M0) 4/5 - - - - - - - + -
69R D II(T3N0M0) 4/5 + - - + + + - + +
79R I I(T2N0M0) 5/5 - - - - - - - - -
3P I II(T3N0M0) 4/7 + - - - - - - - +
11P I III(T3N1M0
)
3/7 + - - - - + + + -
14P M II(T3N0M0) 6/7 + - - + + - - + +
17P I II(T3N0M0) 3/7 - - - - - - - - -
19P D III(T3N1M0
)
3/7 - - - - - - - - -
27P I IV(T4N0M0
)
2/5 - - - - - - - + -
30P I I(T2N0M0) 3/6 - - - - - - - - -
37P I I(T2N0M0) 3/7 - - - - - - - + -
38P I III(T3N2M0
)
3/7 - - - - - - - + -
% present study (number of cases) 27% 0% 0% 13% 20% 13% 7% 60% 27%
mutations (4/15) (0/15) (0/15) (2/15) (3/15) (2/15) (1/15) (9/15) (4/15)
reported in literature (in GCs)d - - - - 22–52% 19–64% 19–24% 42–83% 15–64%
a – I = intestinal type; D = diffuse type; M = mixed type b – according to the TNM classification (Sobin and Wittekind, 1997) c – number of unstable 
/ total tested microsatellites d – data compiled from the references: [17,27,42,50,51,52]
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firmed by sequencing that the abnormal bands are
caused by a deletion of one adenine residue in the poly-
adenine tract (reduction from nine to eight adenines), as
previously shown [24]. The mutation frequency in BLM
may be a low estimate, because we have excluded cases in
which abnormal bands in tumor DNAs were notably
weaker than the normal ones, possibly in consequence of
a large contamination of tumor with nonmalignant cells
or of a low portion of malignant cells displaying the ab-
normality (Fig. 1). Since no BLM mutation was seen in
MMP- tumors, frameshift mutations in the BLM gene
appear to be specifically associated with gastric MMP+
tumors (probability P < 0.01 at Fisher exact test), similar
to the previous well-documented alterations in TGFβ1-
RII, IGFIIR, hMSH3, hMSH6 and BAX genes
[14,16,17,32]. Therefore, our data expand the repertoire
of altered genes associated with MMP+ gastric carcino-
mas.
Frameshifts in other CDRs microsatellites and relations 
with BLM frameshifts
The same panel of MMP+ tumors was also analyzed for
the presence of frameshifts in microsatellites located in
the coding regions of eight other genes (Table 2). We
have found variation in sequence length in TGFβ1-RII,
IGFIIR, hMSH3, hMSH6 and BAX genes, all previously
reported to be altered in MMP+ GCs. Data about the
TGFβ1-RII status for eight (P series in Table 2) of the fif-
teen tumors were previously reported [27]. The observed
mutation frequencies were comparable with those previ-
ously reported for all these genes, with the exception of
IGFIIR, for which we found a low percentage of
frameshifts (Table 2). Interestingly, in comparison with
BLM mutations, only TGFβ1-RII frameshifts were more
frequent (60% vs. 27%, respectively) and BAX
frameshifts were as well as frequent (27%). These data
suggest that frameshifts in BLM are common alterations
in MMP+ GCs. A trend toward an association between
mutations in BLM and mutations in BAX and hMSH3
and/or hMSH6 was observed (Table 2) (P = 0,05 at Fish-
er exact test).
We have also analyzed the RecQL, WRN and CBL genes,
which contain short repeats in their coding regions. The
first two genes are members of the same helicase gene
family as BLM[36,37]. While RecQL is not associated
with any human disease, mutations in the WRN gene are
cause of the Werner syndrome (WS; OMIM 277700), a
rare autosomal recessive disorder clinically character-
ized by premature aging and increased risk for a variety
of neoplasms, and genetically characterized by genomic
instability. CBL is a tyrosine kinase receptor [38], whose
deregulation was associated with oncogenesis [39]. We
have found mutations only in the CBL gene (Fig. 1). Two
samples (69R and 14P) were found to carry a 3 bp inser-
tion in the trinucleotide (ATG)6 repeat of the CBL gene
(data not shown). As we have previously reported [24],
since no frameshift is produced, no functional conse-
quence can be inferred. Both mutations were found in
cancers displaying also BLM frameshifts (Table 2). It is
noteworthy that this subset of tumors show a statistically
significant excess of MSI in coding regions when com-
pared with the MMP+ subset without BLM alterations (P
< 0.001, at Χ2 test) (Table 2).
Discussion
Several studies have documented that alternative path-
ways may exist in gastrointestinal MMP+ and MMP-
cancers characterized by different sets of altered genes
[40]. A gradual model of mutator mutations ("the muta-
tor that mutates the other mutator") was proposed to de-
fine the mutator versus the suppressor pathways in
gastrointestinal tumors [41]. By analyzing the timing of
mutational events in genetically unstable GCs, it was
proposed that the first targets of mismatch repair defi-
ciency are the mononucleotide tracts of TGFβ1-RII and
BAX. The frameshift mutations of hMSH3 and hMSH6
appear to be secondary mismatch repair lesions, which
generate mutations in IGFIIR[42]. The finding that
frameshift mutations at TGFβ1-RII are the most fre-
quent and the IGFIIR are the less frequent in gastric
MMP+ tumors supports to the model in which early
Figure 1
Representative examples of mutations detected in microsat-
ellites at gene coding regions. Case numbers are shown
above each matching normal (N) and tumor (T) DNA pairs.
Arrows indicate the abnormal bands. Note that we have not
considered mutated samples where abnormal bands were
very faint (like in the BLM and BAX genes of tumor sample
30P). Because of the tendency of Taq polymerase to add an
extra nucleotide at the end of the synthesized DNA frag-
ments, PCR products appear sometimes as double bands.
With the exception of BAX frameshift in tumor 69R, no
other mutation appears to be homozygous. However, by
knowing the ratio of malignant cells in tumor sample, we
have previously indicated that the BLM mutation in tumor
69R is also homozygous [24].
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late mutations only in a minor fraction [43]. This finding
is also confirmed in our study (Table 2). BLM frameshift
mutations are associated more frequently with first and
second step alterations proposed in this model, suggest-
ing that they are secondary to mismatch repair defects
(in hMSH3 and/or hMSH6) present in cells which do not
undergo apoptosis (possibly in consequence of BAX in-
activation). Noteworthy, in case 3P, in addition to BLM,
the only frameshifts were found in BAX (see figure 1) and
p53 (data not shown) genes, suggesting that, in some in-
stances, BLM alteration may occur without hMSH3 and/
or hMSH6 mutations, in cells with abnormal p53-medi-
ated pathway of apoptotic response to DNA mismatch.
The involvement of BLM in tumorigenesis outside BS pa-
tients seems conceivable, since this gene appears to act
as a caretaker. BLM mutations are known to cause an in-
creased genomic instability characterized by an elevated
number of chromosomal breaks, gaps and rearrange-
ments and by an excessive number of mutations in both
coding and noncoding regions, likely originated by une-
qual sister-chromatid exchange, characteristic feature of
the Bloom syndrome [44,45]. Accordingly, BS exhibits a
combination of genomic instability and elevated cancer
risk, an association found also in other diseases caused
by defects in caretaker genes (such as HNPCC, WS, atax-
ia-telangiectasia and xeroderma pigmentosum). Similar
to the mutations found in BS, the frameshifts described
in GCs abolish the helicase function of the BLM protein
[24]. BLM protein has a proven DNA unwinding activity
[46] and could be involved in processes that are dis-
turbed in malignant cells, such as DNA replication, re-
combination, chromosome segregation, DNA repair and
transcription. Indeed, the fission yeast BLM gene homo-
logue (radl2 +/rqhl +) was shown to regulate the S-phase
checkpoint and was proposed to couple chromosomal in-
tegrity with cell cycle progression [47,48]. However, the
finding of BLM mutations in MMP+ tumors generates a
paradox: BLM mutations are predicted to generate chro-
mosomal instability while most of the MMP+ tumors are
diploid. Nevertheless, some MMP+ tumors are aneu-
ploid and BLM loss-of-function mutations may have
pleiotropic consequences, possibly affecting also the mi-
crosatellite instability pathway, as suggested by the de-
scription of an increased intra-gene mutations in Bloom
syndrome [44,45]. In suppoprt to our suggestion is the
finding that we have found that BLM is mutated in LoVo
cell line, a colon cancer cell line with both microsatellite
and chromosomal inatability [43]. Much more, it was re-
cently reported that SGS1 gene, the Saccharomyces cer-
evisiae homologue of BLM and WRN, suppresses
genome instability and homeologous recombination and
is redundant with DNA mismatch repair (MMR) for sup-
pressing gross chromosomal rearrangements and for
suppressing recombination between divergent DNA se-
quences [49].
Conclusions
Our results indicate that BLM frameshifts are frequent
alterations in GCs and are specifically associated with
MMP+ tumors displaying at least 2 unstable microsatel-
lites. Mutations in BLM appear to be frequently associat-
ed with frameshifts in BAX and in hMSH6 and/or
hMSH3, and tumors with BLM alterations present a
number of unstable mono- and trinucleotide repeats lo-
cated in coding regions significantly higher than that ob-
served in MMP+ tumors without BLM frameshifts. We
suggest that BLM loss of function by MSI in gastric tu-
mors is an intermediate mutational event, which may in-
crease the instability of a pre-existent unstable genotype.
Methods
Tumor Samples
Fifty primary gastric tumors and their normal paired tis-
sues (blood or normal gastric mucosa) were selected on
the basis of available DNA from a panel of 80 gastric tu-
mors (27, Calin G and Negrini M unpublished data).
When possible, areas of tumor tissue with minimal in-
flammatory cells or minimal stroma, or both, were se-
lected to obtain a neoplastic cell load greater than 50%.
All cases were identified histopathologically as adenocar-
cinomas. Histotype (according to Lauren's classification)
[28] and staging (according to the TNM classification)
[29] was known for 47 out of 50 cases (94%) (Table 1).
Thirty-two cases were of intestinal histotype and 15 cases
of diffuse or mixed type. Twenty tumors were staged I or
II, while 27 were in stage III or IV. Regarding the lymph
node status, eighteen cases were NO and 29 were N-pos-
itive. None of the patients had developed a cancer at an
early age, and none had a family history suggestive of ge-
netic predisposition to cancer. High molecular weight
DNAs was isolated using established procedures [30].
Assessment of MSI
MSI was revealed with two sets of anonymous markers at
loci: (i) D11S1778, D11S1328, D11S922 and D11S1318[24]
or (ii) D2S177, D3S1076, D5S433, D11S904, D17S796
and D18S59[27]. The primers for these dinucleotide mi-
crosatellite loci were obtained from information availa-
ble through the Genome DataBase. PCR amplifications
were carried out as previously described [24,27]. For all
samples the BAT25 and BAT26 microsatellites were an-
alyzed by PCR amplification as described [31]. MSI was
assessed if a mobility shift of PCR products from tumor
DNA compared with the normal counterpart was identi-
fied. Only tumors with at least 2 MSI (>30% of tested mi-
crosatellites) were considered MMP+.
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ing regions (CDRs)
The (A)9 microsatellite located at position 1610–1618 of
BLM cDNA sequence was analyzed for all paired sam-
ples. Briefly, the microsatellite was amplified by PCR us-
ing 50 ng of template DNA, 1 µM of each primer, 1.5 mM
of MgC12, 50 µM each of dATP, dGTP, and dTTP and 5.0
µM of dCTP, 0.1 unit of Taq DNA polymerase, and 1 µCi
[α33P]dCTP in 10 µl of reaction volume. PCR reactions
were carried out for one cycle of 94°C for 5 min followed
by 35 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for
30 s. PCR products from tumor and corresponding con-
trol DNAs were loaded on parallel on 6% acrylamide se-
quencing gels and exposed for visualization by
autoradiography on Kodak X-AR films. Detection of mu-
tations in microsatellites located in the CDRs from eight
other genes (the (A)10 in TGFβ1-RII, the (G)8 in IGFIIR,
the (G)8 in BAX, the (A)8 in hMSH3, the (C)8 in hMSH6,
the (A)9 in RecQL, the (A)8 in WRN, and the (ATG)6 in
CBL) was done as previously described [14,16,17,24,32].
For verification, each PCR was repeated at least twice. A
mutated allele was represented by a band shift of 1 to 3
bp from the normal band with intensity comparable or
greater than that of the wild-type band (Fig. 1).
Sequencing of abnormal products
Genomic DNA fragments exhibiting band shifts were
reamplified under the same conditions except for the
omission of labeled dCTP. Before sequencing, the PCR
products were purified either directly or after separation
in a 2% agarose gel, using Qiagen purification kits. Both
DNA strands were sequenced using PCR primers and an
automated Applied Biosystem 377 sequencing station.
Nucleotide sequences were analyzed using the Wiscon-
sin (GCG) program package version Unix-8.1.
Statistical analysis
The statistical analysis of results was performed using
the Χ2 test or Fisher's exact test. A P value of <0.05 was
considered statistically significant.
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